Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial

Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Updates are limited to cosmetic and layout changes and do not affect core study information such as design, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-10-27T21:08:33.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    - Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.
    Difference
    2%
    Check dated 2025-10-06T08:24:10.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    - Added a new page revision tag (v3.1.0). - Removed a specific medical condition term (Undifferentiated pleomorphic sarcoma).
    Difference
    0.1%
    Check dated 2025-09-29T05:12:36.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Page version updated from v3.0.1 to v3.0.2 and the 'Back to Top' link was removed. No substantive content changes were detected.
    Difference
    0.1%
    Check dated 2025-09-14T23:20:58.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-07T20:00:03.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The web page has been updated to include new facility and location information, as well as detailed results and metrics related to a clinical study on undifferentiated pleomorphic sarcoma, including survival rates and response rates. Notably, the study now includes specific publication references and updated reporting dates.
    Difference
    18%
    Check dated 2025-08-31T12:40:21.000Z thumbnail image

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.